Findings in over 3,000 subjects demonstrate highly sensitive and specific detection of multiple cancers at the earliest stages
Data demonstrates strong performance in stage I detection of breast and prostate cancers, overcoming early-stage detection limitations of other blood-based approaches
PALO ALTO, Calif.–(BUSINESS WIRE)–Exai Bio today announced new data from a 3,300 subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample. Notably, Exai’s platform maintained high sensitivity and specificity in both independent training and testing cohorts, highlighting the strength of its unique generative AI technology. In the independent testing cohort, overall stage I sensitivity across eight cancer types was 87% at 95% specificity. These data will be presented at a poster session today at the American Society for Clinical Oncology (ASCO) 2023 annual meeting.
“These results demonstrate that Exai’s RNA- and AI-based platform can detect stage I cancer at very high sensitivity across multiple cancers while also maintaining the high specificity which is required for real-world clinical utility,” said Patrick Arensdorf, Chief Executive Officer of Exai Bio. “Exai is developing blood tests that have both high accuracy and cancer biology insights to improve cancer care.”
“This large, rigorously designed study represents a significant achievement in the field of early cancer detection,” stated Lee Schwartzberg, M.D., Chief, Medical Oncology and Hematology at the Renown Health-Pennington Cancer Institute. “The results demonstrate that Exai’s platform may close the performance gap of other blood-based approaches and deliver what patients and clinicians need: high cancer detection rates at early stages coupled with fewer false positives.”
Exai’s multi-cancer early detection (MCED) study analyzed eight cancer types including lung, stomach, pancreas, kidney, colorectal, breast, prostate, and bladder, thus representing the majority of the cancer burden on society. The study demonstrates successful detection of stage I breast and prostate cancers which, to date, have both been extremely challenging to detect at early stages using other blood-based approaches. When a cancer signal was detected in the testing cohort, Exai’s platform could identify the tissue of origin with 88% accuracy using the top predicted cancer type and 95% accuracy considering the top two predictions.
In addition to the MCED data, Exai’s abstract entitled “Consensus molecular subtypes and orphan non-coding RNAs in colorectal cancer” was published in the 2023 ASCO Annual Meeting proceedings. These data build upon Exai’s previously published subtyping data in breast cancer, demonstrating that oncRNAs are also predictive of detection of colorectal cancer subtypes. Providing subtype information from a blood test in both initial diagnosis and treatment monitoring settings has the potential to both improve clinical decision making and expand therapeutic options for patients.
The new MCED and colorectal cancer data at ASCO further expand the growing body of evidence that Exai’s platform can be used across multiple tumor types and clinical applications, all using standard blood samples. Previously, Exai has presented non-small lung cancer data at the American Association for Cancer Research (AACR) meeting 2023, breast cancer early detection and screening data at the San Antonio Breast Cancer Symposium (SABCS) 2022, monitoring and molecular residual disease detection data in breast cancer at SABCS 2021, and colorectal cancer early detection and screening data at the 2022 European Society for Medical Oncology (ESMO) meeting.
Exai’s platform uses RNA sequencing to identify a novel category of cancer-associated, small non-coding RNAs, termed orphan non-coding RNAs (oncRNAs). OncRNAs are actively secreted from living cancer cells and are stable and abundant in the blood of cancer patients. Exai has created a catalog of hundreds of thousands of oncRNAs and thousands of patient oncRNA profiles, spanning all major cancer types. When combined with proprietary artificial intelligence technology, the Exai platform has multiple technical and operational advantages over tests that focus on circulating tumor DNA. These include superior sensitivity and specificity, as well as the ability to reveal dynamic changes in the biology of a patient’s tumor over time. Exai’s universal platform can be used across multiple cancer care settings such as screening and early detection, monitoring, molecular residual disease and therapy selection.
ASCO Poster Details
Poster Title: Detection of early-stage cancers using circulating orphan non-coding RNAs in blood
Poster ID: 249
Abstract Number: 3051
Session Title: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Authors: Mehran Karimzadeh, Jeffrey Wang, Taylor B. Cavazos, Lee S. Schwartzberg, Michael Multhaup, Jeremy Ku, Xuan Zhao, Jieyang Wang, Kathleen Wang, Rose Hanna, Patrick Arensdorf, Kimberly H. Chau, Helen Li, Hani Goodarzi, Lisa Fish, Fereydoun Hormozdiari, Babak Alipanahi
About Exai Bio
Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. For more information, please visit us on www.exai.bio and follow us on Twitter and LinkedIn.
Contacts
Kim Maxwell Brown
[email protected]
(617) 960-6685
